hero section gradient
15 handpicked stocks

Enterprise AI Revolution

Tap into the massive corporate spending wave on artificial intelligence and digital transformation. These carefully selected stocks span IT consulting, cloud infrastructure, and the hardware powering the next generation of business technology.

Author avatar

Han Tan | Market Analyst

Published on July 2

Your Basket's Financial Footprint

Summary of the basket's total market capitalisation and large-cap dominance, with concise investor takeaways.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking to broad-market performance than small-cap baskets.
  • Tends to serve as a core, long-term holding to provide stable exposure, not as speculative short-term trading.
  • Likely to deliver steady, long-term appreciation rather than rapid, speculative upside in the near term.
Total Market Cap
  • MSFT: $3.85T

  • NVDA: $4.40T

  • PLTR: $430.42B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Accenture's $1.5 billion in new AI bookings confirms that businesses are investing heavily in digital transformation despite economic uncertainty. This creates opportunities across the entire AI ecosystem, from consultants implementing the technology to the hardware manufacturers building the infrastructure.

2

What You Need to Know

This collection targets long-term growth tied to corporate technology upgrade cycles. It includes diverse companies across the AI value chain, from IT service providers to cloud platforms and semiconductor manufacturers, offering balanced exposure to the enterprise AI revolution.

3

Why These Stocks

These companies were selected based on their strategic positioning to benefit from increased enterprise AI spending. The basket includes industry bellwethers, their key partners, and direct competitors who are all poised to capture value from the accelerating corporate investment in AI technologies.

Why You'll Want to Watch These Stocks

💰

Billion-Dollar AI Spending Wave

Accenture's $1.5 billion in new AI bookings is just the beginning. Companies across industries are racing to adopt AI, creating massive revenue opportunities for the firms in this basket.

🔄

The Unstoppable Upgrade Cycle

Corporate tech upgrades aren't optional anymore—they're survival. This technology refresh cycle is driving predictable, long-term growth that could outlast broader economic uncertainty.

🧩

The Full AI Ecosystem

From the consultants designing AI strategies to the chip makers powering the hardware, this basket gives you exposure to every layer of the enterprise AI revolution, not just one piece.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions